NCT02124668View on ClinicalTrials.gov

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 23, 2014

Primary Completion Date

May 25, 2017

Study Completion Date

May 25, 2017

Conditions
Castration-Resistant Prostate CancerProstate Cancer
Interventions
DRUG

Enzalutamide

oral

Trial Locations (4)

115478

Site RU70002, Moscow

125284

Site RU70003, Moscow

0144

Site GE99503, Tbilisi

0159

Site GE99502, Tbilisi

All Listed Sponsors
collaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | Biotech Hunter | Biotech Hunter